Drug recall · July 29, 2026
Cetirizine Hydrochloride Tablets USP 5 mg recall
Why: Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Cetirizine Hydrochloride Tablets USP 5 mg, 100-count bottle, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-401-10.
- Lots / codes
Lots: GY825029, GY825030, GY825031, GY825032, expires: 2028-OCT
- Quantity
- 34,020 100-count bottles.
- Company
- JB Chemicals and Pharmaceuticals Ltd, Mumbai, N/A
- Distribution
- Nationwide in the USA
- Initiated
- June 24, 2026 · Voluntary: Firm initiated
- Classified
- August 3, 2026
- Reported
- July 29, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Cetirizine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.